论文部分内容阅读
目的探讨克林霉素膦酸酯对肺癌合并下呼吸道感染的治疗效果。方法对我院1996年至2003年间收治的50例肺癌合并下呼吸道感染患者使用克林霉素膦酸酯治疗的情况进行分析调查,对下呼吸道感染类型以及痰培养结果敏感性进行分析总结。结果克林霉素膦酸酯对肺癌合并下呼吸道感染有效率达86.0%,临床分离菌培养对克林霉素膦酸酯的药物敏感性达93.8%。结论克林霉素膦酸酯对肺癌合并下呼吸道感染有较好效果,尤其对肺癌引起的阻塞性肺炎治疗效果显著,可作为一线经验性用药。
Objective To investigate the therapeutic effect of clindamycin phosphonate on patients with lung cancer complicated with lower respiratory tract infection. Methods 50 cases of lung cancer with lower respiratory tract infection treated with clindamycin phosphonate in our hospital from 1996 to 2003 were analyzed and analyzed to analyze the types of lower respiratory tract infection and the sensitivity of sputum culture results. Results Clindamycin phosphonate had an effective rate of 86.0% for lung cancer complicated with lower respiratory tract infection, and the drug sensitivity of clindamycin phosphonate to clinical isolates was 93.8%. Conclusion Clindamycin phosphonates have a good effect on lung cancer with lower respiratory tract infection, especially for the treatment of obstructive pneumonia caused by lung cancer, which can be used as first-line empirical medication.